Dr. Martin Godbout is presently a member of the board of directors of several Canadian biopharmaceutical companies, foundations and scientific Canadian organizations including Acasti Pharma, AmorChem, AngioChem, AsmaCure, MethylGene (chairman), Génome Québec (chairman), BioContact, BioQuébec, FQRS, Montréal In Vivo et la Fondation de l’ataxie de Charlevoix. Dr. Godbout was the Founder, President & CEO of Genome Canada, a private, not-for-profit Corporation, dedicated to investing and implementing a national strategy in genomics and proteomics research in Canada. He also was a member of the Board of the “Conseil de la Science et de la Technologie du Québec” (1996-2004) and of the National Science and Engineering Research Council of Canada (1999-2002). In 1994 he founded BioContact Québec, an international biopharmaceutical partnership symposium. From 1997, Dr. Godbout was the Senior Vice-President of BioCapital, a Canadian venture capital firm specializing in seed-to-mezzanine stage private financing of companies demonstrating strong potential in the healthcare and biotechnology sectors. Prior to that position, he was President and General Manager of Société Innovatech Québec, a $60 million technology investment fund.In August 2005, Dr. Godbout was named Officer of the Order of Canada. He is the recipient of numerous awards including the Grand Prix Recherche (1991) from the Quebec Foundation for Mental Disorder for his previous work on Alzheimer’s disease and the “Prix Summa” from the Faculty of Science and Engineering at Laval University (1994). Martin Godbout holds a B.Sc. in biochemistry and a Ph.D. in physiology and molecular endocrinology from Laval University. He received a postdoctoral fellowship from the Medical Research Council (MRC) of Canada and went to San Diego, California, where he was trained in Neuromolecular Biology, at The Scripps Research Institute. He was an Assistant Professor at the Department of Psychiatry, Faculty of Medicine, Laval University and was Assistant Managing Director responsible for biopharmaceutical industry relations at the Research Centre of Centre Hospitalier de l’Université Laval (CHUL). Dr. Godbout has authored or co-authored more than 60 publications and abstracts, and has been invited as a speaker at numerous scientific and financial conferences. In March 2006, Dr. Godbout was shortlisted by the editors of Nature Biotechnology, as one of twenty nominees who have made the most remarkable and influential contribution to biotech in the past ten years in the category “Biobusiness in the rest of the world”.

Dr. Baum was appointed President and Chief Executive Officer and Board Member of MethylGene in November 2012. Prior to joining MethylGene he was Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division. Dr. Baum was at Pfizer since 2003, serving in roles of increasing responsibility including as Vice President and Head of Oncology Development and as Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. He was responsible for the development of the oncology portfolio, including Axitinib (Inlyta®), Crizotinib (Xalkori®) and the approval of sunitinib (Sutent®) for the treatment of gastrointestinal stromal tumor (GIST) and renal cell carcinoma. Prior to joining Pfizer, Dr. Baum was responsible for the Phase I-IV development of several oncology compounds at Schering-Plough, including temozolomide (Temodar®) which was approved for the treatment of patients with advanced brain tumors. His career has included academic and hospital positions at Stanford and Emory universities, as well as positions of increasing responsibility within the pharmaceutical industry (Systemix, Searle, and Schering-Plough and Pfizer). Dr. Baum received his M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine in St. Louis, Missouri and completed his post-doctoral work and residency at Stanford University, California. Dr. Baum has received research support from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts, and holds a number of patents and patent applications.

Henry J. Fuchs, MD is currently Executive Vice President and Chief Medical Officer of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and is a seasoned biotech drug development executive. From 2005 to 2008, Dr. Fuchs was Executive Vice President and Chief Medical Officer of Onyx Pharmaceuticals (NASDAQ: ONXX), overseeing expanded development of the kinase inhibitor Nexavar and other key development programs. From 1996 to 2005, Dr. Fuchs served in multiple roles of increasing responsibility at Ardea Biosciences (NASDAQ: RDEA), first as Vice President, Clinical Affairs, then as President and Chief Operating Officer, and finally as Chief Executive Officer. From 1987 to 1996, Dr. Fuchs held various positions at Genentech where, among other responsibilities, he led the clinical program that resulted in the approval of Pulmozyme. Dr. Fuchs was also responsible for the Phase III development program that led to the approval of Herceptin to treat metastatic breast cancer. Dr. Fuchs received an M.D. degree from George Washington University and a B.A. degree in biochemical sciences from Harvard University.

Dr. Lappe brings 29 years of drug discovery experience in the pharmaceutical and biotech industries to MethylGene. Before joining Tavistock Life Sciences in early 2012, he was Group Sr. Vice President, Pfizer Worldwide Research and Development and Chief Scientific Officer for CovX in San Diego, California. Dr. Lappe was responsible for the advancement of three novel protein bio-conjugates through his work at CovX that are now in clinical testing as well as two additional clinical candidates in late stage preclinical development. Dr. Lappe was also responsible for the continued growth and productivity of Pfizer’s four internal Biotech Units, Rinat, the Center for Integrated Biology and Biotherapeutics and the Oligonucleotide Technology Unit. He served as Co-lead of the integration of Wyeth R&D after the acquisition by Pfizer in 2009. Prior to joining CovX, Dr. Lappe served as Vice President for cardiovascular and metabolic diseases at Pharmacia where he contributed to the registration of Inspra®, a novel aldosterone receptor antagonist. Prior to joining Pharmacia, he held positions of increasing responsibility with Wyeth, Rorer Central Research, CIBA Geigy and Searle Pharmaceuticals. Dr. Lappe received his PhD in Pharmacology from Indiana University and his BA from Blackburn College.

Peggy Mulligan most recently served as Executive Vice President and Chief Financial Officer of Valeant Pharmaceuticals International, Inc (formerly Biovail Corporation), a multinational pharmaceutical company listed on both the New York Stock Exchange and Toronto Stock Exchange. During her tenure, she co-led the merger and subsequent integration with Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX). She is currently a member of the Board of Directors of Ontario Power Generation Inc. (“OPG”) and Chair of OPG’s Human Resources & Compensation Committee. From 2005 to 2007 Peggy served as Executive Vice President, Chief Financial Officer and Treasurer of Linamar Corporation (TSX:LNR). Previously Peggy spent eleven years in various roles at the Bank of Nova Scotia (NYSE/TSX: BNS), most recently as Executive Vice President, Systems & Operations. Before joining the Bank of Nova Scotia she was an Audit Partner with Price Waterhouse. In 2003 and 2004 Ms. Mulligan was named one of Canada’s Top 100 Most Powerful Women by the Women’s Executive Network.She holds a B. Math (Honours) from the University of Waterloo and she is a Fellow of the Institute of Chartered Accountants (FCA) of Ontario.

Peter A. Thompson, M.D. is a biotechnology executive, investor and entrepreneur. He is a Venture Partner at Orbimed Advisors and the founder and Managing Director of Strategicon Partners, an investment and management services company. He co-founded Trubion Pharmaceuticals (NASDAQ: TRBN), and served as CEO and Chairman from its inception through its successful IPO and as a public company until his retirement in 2009. Dr. Thompson is the former Vice President & General Manager of Chiron Informatics at Chiron Corporation and held various executive positions in Becton Dickinson, including Vice President, Research and Technology Department prior to joining Chiron. Dr. Thompson is a co-founder of iMetrikus (now Numera), a clinical decision support company, where he served as CEO and Chairman. He serves as a Director on the Boards of Anthera Pharmaceuticals (NASDAQ: ANTH), Methylgene (TSX: MYG), Response Biomedical (TSX: RBM), Cleave Biosciences (Co-Founder), Principia Biosciences, & CoDa Therapeutics. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an inventor on numerous patents, a board-certified internist and oncologist, and an Affiliate Professor of Neurosurgery at the University of Washington. He was on faculty at the National Cancer Institute trained in internal medicine training at Yale University and received his medical degree from Brown University.